| 伊马替尼在胃肠道间质瘤治疗中的应用 |
| |
| 引用本文： | 尚雯,陶霞,刘皋林. 伊马替尼在胃肠道间质瘤治疗中的应用[J]. 中国新药与临床杂志, 2004, 23(11): 806-810 |
| |
| 作者姓名： | 尚雯 陶霞 刘皋林 |
| |
| 作者单位： | 中国人民解放军第二军医大学附属长征医院,药学部,上海,200003 |
| |
| 摘 要： | 伊马替尼为苯胺嘧啶的衍生物 ,是一特异性的酪氨酸激酶抑制剂 ,合成于 1992年 ,2 0 0 1年 5月被FDA批准用于治疗慢性粒细胞白血病。最近 ,伊马替尼又被FDA批准用于治疗胃肠道间质瘤(GIST) ,本文主要综述该药的药效学、药动学以及在GIST治疗中的疗效、不良反应和耐受性。
|
| 关 键 词： | 胃肠肿瘤 药物疗法 药动学 伊马替尼 胃肠道间质瘤 |
| 文章编号： | 1007-7669(2004)11-0806-05 |
Application of imatinib in treatment of gastrointestinal stromal tumour |
| |
| SHANG Wen,TAO Xia,LIU Gao-lin. Application of imatinib in treatment of gastrointestinal stromal tumour[J]. Chinese Journal of New Drugs and Clinical Remedies, 2004, 23(11): 806-810 |
| |
| Authors: | SHANG Wen TAO Xia LIU Gao-lin |
| |
| Abstract: | Imatinib mesylate (imatinib) is derivative of 2-phenylaminopyrimidine, that is a special inhibitor of the tyrosine kinases which was synthesized in 1992. It was approved by the food and drug administration in USA for the treatment of chronic myeloid leukaemia (CML) in May 2001 and recently for unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST). This paper reviews the progress in the pharmacodynamics, pharmacokinetics, clinical effect of imatinib mesylate for the treatment of GIST and its adverse reactions and tolerance. |
| |
| Keywords: | gastrointestinal neoplasms drug therapy pharmacokinetics imatinib gastrointestinal stromal tumour |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
